PEN vs TARS
Penumbra, Inc. vs Tarsus Pharmaceuticals, Inc. — AI-powered side-by-side comparison
PEN
Penumbra, Inc.
67
Buy
VS
TARS
Tarsus Pharmaceuticals, Inc.
63
Buy
| Metric | PEN | TARS |
|---|
| AI Score |
67
|
63
|
| Price |
$326.07
|
$69.50
|
| P/E Ratio |
79.78×
|
-63.72×
|
| ROE |
12.4%
|
-19.3%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
67.8%
|
90.6%
|
| Debt / Equity |
0.14×
|
0.26×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
79.6
|
80.7
|
| Beta |
0.701
|
0.512
|
| Expected Upside |
+6.3%
|
—
|
AI Committee View
Current Innellis committee reasoning for PEN versus TARS.
PEN leads by 4 points.
PEN scores 67/100 (Buy) versus TARS at 63/100 (Buy).
PEN Committee View
80% agreement
5 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is 2 consecutive earnings misses -- execution concerns. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- 2 consecutive earnings misses -- execution concerns — Growth
- RSI at 80 is in overbought territory — Technical
TARS Committee View
50% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Revenue growing 105.2% YoY -- genuine top-line momentum — Growth
- MACD histogram positive -- bullish momentum — Technical
- Low leverage (debt-to-equity 0.21) -- balance sheet can absorb a shock — Risk
Bear Case
- Price-to-book of 10.1x prices in significant intangible value — Value
- ROE of only -13.5% -- cheap may mean cheap for a reason — Value
- RSI at 81 is in overbought territory — Technical